Can fake ayurveda medicines cure sexual disorders, impotency? Seizures by Drug Control Admn

HYDERABAD: The Telangana Drugs Control Administration (DCA) has seized eight varieties of ayurvedic medicines from Nalgonda for making misleading claims on their labels and violating the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.

The medicines, manufactured by Lifecare Ayurvedic from Rajasthan, made claims to treat diabetes, kidney stones, sexual impotence, obesity, asthma, menstrual disorders, and vision problems, which are prohibited under the Act.

The seized products are

  • Diab Amrit Capsules (claimed to treat diabetes)
  • Stone Crush Capsules and Syrup (claimed to treat kidney stones)
  • Sleemocare Kit Powder and Capsule (claimed to treat obesity)
  • Sperm Grow Kit Powder and Capsule (claimed to treat sexual impotence)
  • Migrocare Capsules (claimed to treat vision problems)
  • Cysto Care Syrup (claimed to treat irregular menstruation)
  • Asthma Care Capsules (claimed to treat asthma)

The raid took place at Sri Siddhi Vinayaka Medical Hall in Nalgonda. DCA officials said that the seized medicines were worth Rs 2,750.

“Persons who make misleading advertisements regarding drugs for treatment of certain diseases and disorders are punishable under Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, with imprisonment which may extend to six months, or with fine, or with both,” the DCA said.

The authorities said that further investigation was underway and action would be taken against all offenders as per the law.

Related Posts

  • Pharma
  • February 17, 2025
  • 93 views
GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gained by 20 percent on Monday, February 17, as brokerages like ICICI Securities and Motilal Oswal continue to maintain positive rating of the stock. GlaxoSmithKline Pharmaceuticals Ltd…

  • Pharma
  • February 17, 2025
  • 82 views
Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Shares of Glenmark Pharmaceuticals Ltd rose 4% on February 17 after the firm gave a strong guidance for FY26 and it returned to black in the December quarter. The drugmaker…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Wow! What a Change of Heart in Practitioners of Allopathy!

Wow! What a Change of Heart in Practitioners of Allopathy!

GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gain 20% following strong Q3FY25 results

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

US Tariffs on pharma: What are the potential impact on Indian drugmakers

US Tariffs on pharma: What are the potential impact on Indian drugmakers

Twin Health bats a1000 before enters Digital Health NY 100

Twin Health bats a1000 before enters Digital Health NY 100

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%